Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease

Journal of Clinical Oncology

Volumn 34, Issue 2, 2016, Pages 151-159

  Geyer, Holly ^a   Scherber, Robyn ^a   Kosiorek, Heidi ^a   Dueck, Amylou C ^a   Kiladjian, Jean Jacques ^b   Xiao, Zhijian ^h   Slot, Stefanie ⁱ   Zweegman, Sonja ⁱ   Sackmann, Federico ^m   Fuentes, Ana Kerguelen ⁿ   Hernández Maraver, Dolores ⁿ   Döhner, Konstanze ^q   Harrison, Claire N ^u   Radia, Deepti ^u   Muxi, Pablo ^w   Besses, Carlos ^o   Cervantes, Francisco ^p   Johansson, Peter L ^x   Andreasson, Bjorn ^x   Rambaldi, Alessandro ^aa   Barbui, Tiziano ^aa   Bonatz, Karin ^r   Reiter, Andreas ^r   Boyer, Francoise ^c   Etienne, Gabriel ^d   Ianotto, Jean Christophe ^e   Ranta, Dana ^f   Roy, Lydia ^g   Cahn, Jean Yves ^f   Maldonado, Norman ^ae   Barosi, Giovanni ^ab   Ferrari, Maria L ^aa   Gale, Robert Peter ^v   Birgegard, Gunnar ^y   Xu, Zefeng ^h   Zhang, Yue ^h   Sun, Xiujuan ^h   Xu, Junqing ^h   Zhang, Peihong ^h   Te Boekhorst, Peter A W ^j   Commandeur, Suzan ^k   Schouten, Harry ^l   Pahl, Heike L ^s   Griesshammer, Martin ^t   Stegelmann, Frank ^q   Lehmann, Thomas ^af   Senyak, Zhenya ^ag   Vannucchi, Alessandro M ^ad   Passamonti, Francesco ^ac   Samuelsson, Jan ^z   Mesa, Ruben A ^a   more..

^a MAYO CLINIC   (United States)

^b SAINT LOUIS HOSPITAL   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d INSTITUT BERGONIÉ   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f GRENOBLE UNIVERSITY HOSPITAL   (France)

^g POITIERS UNIVERSITY HOSPITAL   (France)

^h PEKING UNION MEDICAL COLLEGE   (China)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Fundacion para Combatir La Leucemia   (Argentina)

ⁿ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^o HOSPITAL DEL MAR   (Spain)

^p UNIVERSITY OF BARCELONA   (Spain)

^q UNIVERSITY HOSPITAL ULM   (Germany)

^r UNIVERSITY OF HEIDELBERG   (Germany)

^s UNIVERSITY OF FREIBURG   (Germany)

^t KLINIKUM MINDEN   (Germany)

^u GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^v IMPERIAL COLLEGE LONDON   (United Kingdom)

^w British Hospital Montevideo   (Uruguay)

^x NU Hospital Organization   (Sweden)

^y UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^z STOCKHOLM SÖDER HOSPITAL   (Sweden)

^aa OSPEDALI RIUNITI   (Italy)

^ab FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^ac UNIVERSITY OF PAVIA   (Italy)

^ad OSPEDALE DI CIRCOLO   (Italy)

^ae UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^af UNIVERSITY HOSPITAL BASEL   (Switzerland)

^ag MPN Forum   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; HYDROXYUREA; ANTINEOPLASTIC AGENT; JANUS KINASE;

ABDOMINAL DISCOMFORT; ADULT; ANEMIA; BONE PAIN; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE DURATION; FATIGUE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTOSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MIDDLE AGED; NIGHT SWEAT; PALPABLE SPLENOMEGALY; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SPLENOMEGALY; SYMPTOM ASSESSMENT; THROMBOCYTOPENIA; THROMBOCYTOSIS; VALIDATION STUDY; WEIGHT REDUCTION; AGED; ANTAGONISTS AND INHIBITORS; COMPLICATION; FEMALE; GENETICS; MALE; PAIN; PALPATION; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SWEATING; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FATIGUE; FEMALE; FEVER; HUMANS; HYDROXYUREA; JANUS KINASES; MALE; MIDDLE AGED; PAIN; PALPATION; PHLEBOTOMY; POLYCYTHEMIA VERA; PROGNOSIS; PROSPECTIVE STUDIES; PRURITUS; SEVERITY OF ILLNESS INDEX; SPLENOMEGALY; SWEATING; WEIGHT LOSS;

EID: 84954221953     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.62.9337     Document Type: Conference Paper

References (17)

1. Tefferi A, Vardiman JW: Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 22:14-22, 2008
2. Emanuel RM, Dueck AC, Geyer HL, et al: Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: Prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol 30:4098-4103, 2012
3. Mesa RA, Niblack J, Wadleigh M, et al: The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): An international Internetbased survey of 1179 MPD patients. Cancer 109: 68-76, 2007
4. Berlin NI: Diagnosis and classification of the polycythemias. Semin Hematol 12:339-351, 1975
5. Anger BR, Seifried E, Scheppach J, et al: Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases. Klin Wochenschr 67:818-825, 1989
6. Tefferi A, Rumi E, Finazzi G, et al: Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia 27:1874-1881, 2013
7. Emanuel R, Marchioli R, Dueck A, et al: Impact of hematocrit on symptom burden among polycythemia vera patients. European Hematology Association Annual Meeting Abstracts. 276, 2013
8. Marchioli R, Finazzi G, Specchia G, et al: CYTO-PV Collaborative Group: Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 368:22-33, 2013
9. Kiladjian JJ, Chevret S, Dosquet C, et al: Treatment of polycythemia vera with hydroxyurea and pipobroman: Final results of a randomized trial initiated in 1980. J Clin Oncol 29:3907-3913, 2011
10. Alvarez-Larrán A, Pereira A, Cervantes F, et al: Assessment and prognostic value of the European Leukemia Net criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119: 1363-1369, 2012
11. Barosi G, Birgegard G, Finazzi G, et al: A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: Results of a European Leukemia Net (ELN) consensus process. Br J Haematol 148: 961-963, 2010
12. Vannucchi AM, Kiladjian JJ, Griesshammer M, et al: Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med 372: 426-435, 2015
13. Scherber R, Dueck AC, Johansson P, et al: The myeloproliferative neoplasm symptom assessment form (MPN-SAF): International prospective validation and reliability trial in 402 patients. Blood 118:401-408, 2011
14. Scherber RM, Senyak Z, Dueck AC, et al: The impact of medical comorbidities in MPN-related fatigue. Blood 124:1862, 2014
15. Emanuel R, Dueck AC, Geyer HL, et al: Myeloproliferative (MPN) symptom burden response thresholds: Assessment of MPN-SAF TSS quartiles as potential markers of symptom response. Blood 122:4067, 2013
16. Vaidya R, Gangat N, Jimma T, et al: Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol 87:1003-1005, 2012
17. Geyer HL, Scherber RM, Dueck AC, et al: Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: Retrospective assessment in 1,470 patients. Blood 123:3803-3810, 2014